Professor Thomas Rademacher, Co-founder & CEO
Professor Rademacher, MD, PhD, co-founded Emergex and has served as CEO since the Company’s formation.
He is an Emeritus Professor of Molecular Medicine at University College London (UCL) and a serial entrepreneur. Professor Rademacher is considered one of the founders of biotech in the early 1980s (recombinant proteins, monoclonal antibodies, glycobiology) and as an academic scientist has over 200 publications and 50 patents in his name. He was co-Founder of the field of Glycobiology and subsequent Glycobiology Institute in Oxford. He co-founded Oxford GlycoSciences, the first of Oxford University’s biotech spinouts, which, in 1998, was listed on the London Stock Exchange and reached a market capitalisation of £1.7 billion. After moving to UCL, Professor Rademacher founded several biotech spin-out companies, including Rodaris Pharmaceuticals Ltd.
In 2000, he entered into a collaboration with the Spanish Research Council and co-founded the first nanomedicine company, Midatech Ltd. Midatech floated on the AIM and NASDAQ stock exchanges in December 2015.
Professor Rademacher has authored over 200 publications and 50 patents – 19 of which are in the nanomedicine field. In addition to being a world leader in nanomedicine, he is also an expert in foetal-maternal medicine, having produced 25 publications and filed 5 patents related to preeclampsia.
Storme Moore-Thornicroft, Executive Director
Storme Moore-Thornicroft co-founded Emergex and has served as COO since the Company’s formation.
Storme is responsible for business strategy formulation, implementation and execution at Emergex. In addition, she manages corporate and business development, company structure and organization, risk management, local and international partner relations and Board and shareholder relations.
She has operated in the biotechnology sector for over two decades and is particularly experienced in company formation and development. Storme has managed incorporation processes relating to the creation of corporate subsidiaries and other strategic structures such as Joint Ventures in Europe and in the US. She has managed financing processes for a number of early stage companies from corporate strategy and investor introduction through to investment agreement and completion. She also has experienced establishing strategic relationships with governments in South America, the Far East and areas of Africa.
Prior to Emergex, she co-founded Midatech Ltd, taking the role of Vice President, Corporate Management where she was responsible for corporate and business planning, implementation and execution of strategy and operations, resulting in technology development and commercialisation.
In her early career she served at University College London (UCL Business) as IP Manager where she was responsible for the prosecution and maintenance of IP portfolios generated for UCL spin-off companies.
Dr Yixiang Dong, Non-Executive Director
Dr Dong is a chartered accountant and currently working as a Finance Controller at Sky UK.
Prior to that he worked at P&G as a finance manager and at Imperial College as a research scientist. He is also a partner of Trend Investment, a boutique investment firm specialised in biotech.
Dr Dong was trained as a biomedical scientist.
Sergio Pagani, Non-Executive Director
Sergio Pagani is currently Global Head of Commodities at ANZ Banking Group in Singapore and has more than 20 years of experience in international banking, finance and capital markets.
He has an extensive track record of delivering in a variety of senior positions in Zurich, London and Singapore, including at UBS Private Banking, Bankers Trust, Deutsche Bank, Dresdner Kleinwort Wasserstein, and Mitsubishi UFJ.
Sergio is also an active investor in biotech companies and serves as a Director on the Board of RWDC Industries, a Singapore-based company with leading technology in the field of biodegradable biopolymers.
Dr. Finian Tan, Chairman
Dr. Finian Tan founded Vickers Venture Partners of Singapore in 2005 with five other co-founders and is the Company Chairman.
Before starting Vickers, Finian was a Managing Director and Founding Partner at Draper Fisher Jurvetson (DFJ) ePlanet Asia Ventures. During his time at DFJ he led the investment into Baidu and remained its largest backer until the IPO.
Prior to DFJ ePlanet, Finian was Deputy Secretary of Trade and Industry for the Singapore Government where he oversaw the creation of the billion-dollar TIF fund and was subsequently appointed as Chairman of the fund.
As part of his earlier career path, Finian ran J.Aron (Singapore), the trading arm of Goldman Sachs.
Finian received his Doctor of Philosophy and Master of Philosophy in Engineering from Cambridge University. He received his B.Sc. in Engineering from the University of Glasgow, where he won every prize available to be won in all examinations in his years there.
Dr Xinhong Lim, Director
Dr Xinhong Lim joined Vickers in 2015 and is based in Silicon Valley.
He has led investments into companies in the life sciences, medical device, AI and advanced materials sectors, and advises on fund strategy in these areas. He serves on the Board of Emergex as well as RWDC Industries, an advanced sustainable biopolymers company.
Dr Lim received his Ph.D. in Developmental Biology from Stanford University and a Certificate in Innovation and Entrepreneurship from the Stanford Graduate School of Business. He is an Assistant Professor (Adjunct) at the Skin Research Institute of Singapore (SRIS) and NTU LKC School of Medicine. His work has been published and cited in the most prestigious scientific journals, including Nature and Science, as well as highlighted in the international press, including by CNN and BBC. He is the recipient of numerous awards, including the Singapore National Academy of Sciences Young Scientist Award and the Ten Outstanding Young Singaporeans Award (Medical Innovation).
Dr Anthony Sedgwick, Non-executive director
Dr. Anthony (Tony) Sedgwick is an experienced biotech executive, bringing over 40 years of international experience in the sector to Emergex. He was head of anti-inflammatory Biology at Roche between 1986-1990, and after a 2 year period in Marketing at Roche became Global head of Clinical operations until 2002.
At Roche, Tony was responsible for clinical development, leading to the launch of several products including Invirase® and Tamiflu® which have had significant impact both medically and commercially.
During his career, Tony has been the Chief Executive Officer of four biotechnology companies, Cambridge Biotechnology (2002-2005), DanioLabs (2005-2007), Novacta (2007-2011) and Silence Therapeutics (2011-2012), two of which successfully exited. He has also held Chairman positions at several companies including Plastid AS (2008-2011), ThioLogics (2011-2013) and most recently at Cotton Mouton Diagnostics (2017-2019).
During the past few years, Tony has specialised in ‘trusted’ advisor roles for CEOs and heads of R&D.
Tony holds a PhD in Experimental Pathology from St Bartholomew’s Hospital Medical School in London and is a Fellow of the Royal College of Pathologists and an honorary Professor at Swansea University Medical School.
